Literature DB >> 56421

Characterization of amyloid fibril proteins from medullary carcinoma of the thyroid.

K Sletten, P Westermark, J B Natvig.   

Abstract

Amyloid fibrils were studied from two different tissues of medullary carcinoma of the thyroid (MCT). The fibrils mainly consisted of a low molecular weight protein, AMCT, which was immunologically distinct and did not react with various antisera against known amyloid fibril proteins. A specific antiserum raised against the MCT amyloid proteins gave a reaction of identity with the degraded MCT amyloid fibrils from two patients, as well as with the isolated AMCT protein, but showed no reaction with other known amyloid proteins. The AMCT protein had a blocked N terminus, but the sequence analysis of a cyanogen bromide fragment revealed identity with human calcitonin in the 11 positions studied. Although the amino acid composition was similar, there were also distinct differences, and the mol wt of 5,700 daltons was considerably larger than that of calcitonin. For these reasons the AMCT protein may represent a prohormone of calcitonin.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 56421      PMCID: PMC2190167          DOI: 10.1084/jem.143.4.993

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  10 in total

1.  The genesis of apudamyloid in endocrine polypeptide tumours: histochemical distinction from immunamyloid.

Authors:  A G Pearse; S W Ewen; J M Polak
Journal:  Virchows Arch B Cell Pathol       Date:  1972

2.  Molecular weight analysis of oligopeptides by electrophoresis in polyacrylamide gel with sodium dodecyl sulfate.

Authors:  R T Swank; K D Munkres
Journal:  Anal Biochem       Date:  1971-02       Impact factor: 3.365

3.  Isolation of a glucagon-containing peptide: primary structure of a possible fragment of proglucagon.

Authors:  H S Tager; D F Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  1973-08       Impact factor: 11.205

4.  The complete amino-acid sequence of non-immunoglobulin amyloid fibril protein AS in rheumatoid arthritis.

Authors:  K Sletten; G Husby
Journal:  Eur J Biochem       Date:  1974-01-03

5.  [Human calcitonin. Structure of calcitonin M and D].

Authors:  R Neher; B Riniker; W Rittel; H Zuber
Journal:  Helv Chim Acta       Date:  1968       Impact factor: 2.164

6.  Amyloid fibril protein subunit, "protein AS": distribution in tissue and serum in different clinical types of amyloidosis including that associated with myelomatosis and Waldenström's macroglobulinamia.

Authors:  G Husby; K Sletten; T E Michaelsen; J B Natvig
Journal:  Scand J Immunol       Date:  1973       Impact factor: 3.487

7.  Amyloid of medullary carcinoma of the thyroid; partial characterization.

Authors:  P Westermark
Journal:  Ups J Med Sci       Date:  1975       Impact factor: 2.384

8.  The characterization of soluble amyloid prepared in water.

Authors:  M Pras; M Schubert; D Zucker-Franklin; A Rimon; E C Franklin
Journal:  J Clin Invest       Date:  1968-04       Impact factor: 14.808

9.  The P-component of amyloid of human islets of langerhans.

Authors:  P Westermark; M Skinner; A S Cohen
Journal:  Scand J Immunol       Date:  1975       Impact factor: 3.487

10.  New, third class of amyloid fibril protein.

Authors:  G Husby; J B Natvig; K Sletten
Journal:  J Exp Med       Date:  1974-03-01       Impact factor: 14.307

  10 in total
  55 in total

1.  Converting the highly amyloidogenic human calcitonin into a powerful fibril inhibitor by three-dimensional structure homology with a non-amyloidogenic analogue.

Authors:  Giuseppina Andreotti; Rosa Maria Vitale; Carmit Avidan-Shpalter; Pietro Amodeo; Ehud Gazit; Andrea Motta
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

2.  Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets.

Authors:  A Lukinius; E Wilander; G T Westermark; U Engström; P Westermark
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

3.  Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin.

Authors:  Susan B Fowler; Stephen Poon; Roman Muff; Fabrizio Chiti; Christopher M Dobson; Jesús Zurdo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-08       Impact factor: 11.205

Review 4.  Amyloidogenesis of natively unfolded proteins.

Authors:  Vladimir N Uversky
Journal:  Curr Alzheimer Res       Date:  2008-06       Impact factor: 3.498

5.  Age-related accumulation of amyloid inclusions in adrenal cortical cells.

Authors:  L Eriksson; P Westermark
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

6.  Amyloid deposits in bioprosthetic cardiac valves after long-term implantation in man. A new localization of amyloidosis.

Authors:  Y A Goffin; E Gruys; G D Sorenson; F Wellens
Journal:  Am J Pathol       Date:  1984-03       Impact factor: 4.307

7.  Senile cerebral amyloid. Prealbumin as a common constituent in the neuritic plaque, in the neurofibrillary tangle, and in the microangiopathic lesion.

Authors:  T Shirahama; M Skinner; P Westermark; A Rubinow; A S Cohen; A Brun; T L Kemper
Journal:  Am J Pathol       Date:  1982-04       Impact factor: 4.307

8.  Effect of nanomolar concentrations of sodium dodecyl sulfate, a catalytic inductor of alpha-helices, on human calcitonin incorporation and channel formation in planar lipid membranes.

Authors:  Silvia Micelli; Daniela Meleleo; Vittorio Picciarelli; Maria G Stoico; Enrico Gallucci
Journal:  Biophys J       Date:  2004-08       Impact factor: 4.033

9.  The potassium permanganate method. A reliable method for differentiating amyloid AA from other forms of amyloid in routine laboratory practice.

Authors:  M H van Rijswijk; C W van Heusden
Journal:  Am J Pathol       Date:  1979-10       Impact factor: 4.307

Review 10.  Amyloid deposits in a prolactin-producing pituitary adenoma.

Authors:  P L Bononi; A J Martinez; P B Nelson; J A Amico
Journal:  J Endocrinol Invest       Date:  1993-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.